Gries Financial LLC Acquires 1,853 Shares of Pfizer Inc. (NYSE:PFE)

Gries Financial LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 6.8% in the 4th quarter, HoldingsChannel reports. The firm owned 29,246 shares of the biopharmaceutical company’s stock after purchasing an additional 1,853 shares during the quarter. Gries Financial LLC’s holdings in Pfizer were worth $776,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Retirement Wealth Solutions LLC purchased a new stake in Pfizer during the 4th quarter valued at $26,000. Gladius Capital Management LP increased its stake in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP purchased a new stake in Pfizer in the second quarter worth $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in Pfizer in the third quarter worth $35,000. Finally, Joseph Group Capital Management grew its position in shares of Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 771 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PFE. Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Wolfe Research assumed coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Citigroup lowered their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday. Sanford C. Bernstein assumed coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Finally, StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Down 0.4 %

Pfizer stock opened at $26.65 on Thursday. The company has a market capitalization of $151.00 billion, a price-to-earnings ratio of 36.01, a PEG ratio of 0.64 and a beta of 0.64. The company’s fifty day moving average price is $26.18 and its two-hundred day moving average price is $27.91. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company’s revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.17) earnings per share. On average, analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.46%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.